TABLE 4.

Susceptibilities of gram-negative bacteria isolated from lower respiratory tract specimens of hospitalized patients in four European countries, Canada, and the United States to antimicrobials^a

Organism	Antimicrobial agent	France		Germany		Italy		Spain		Canada		United States
		No. of isolates	% Susceptible	No. of isolates	% Susceptible	No. of isolates	% Susceptible	No. of isolates	% Susceptible	No. of isolates	% Susceptible	No. of isolates	% Susceptible
E. coli	Cefotaxime	2,416	99.6	2,631	98.0	685	94.0	815	96.7	1,033	95.5	3,249	95.8
	Ceftazidime	2,555	98.4	1,508	97.9	899	93.1	737	97.3	1,418	97.0	4,716	93.8
	Ceftriaxone	134	97.8	213	100	674	92.6	NAb	NA	1,381	96.8	4,600	96.2
	Ciprofloxacin	2,300	93.6	2,200	83.8	934	90.9	841	84.7	1,719	91.2	5,042	88.0
	Gentamicin	2,422	96.2	2,548	92.9	931	94.4	836	92.1	1,974	94.0	6,218	90.6
	TMP-SMX	2,212	77.0	2,489	73.8	893	79.2	836	72.0	2,005	83.6	6,012	77.3
Klebsiella spp.	Cefotaxime	1,160	96.5	3,615	92.7	901	90.0	617	93.0	1,367	97.6	6,506	92.3
	Ceftazidime	1,287	94.7	2,065	92.0	1,103	80.3	562	94.3	1,975	98.0	9,459	89.9
	Ceftriaxone	89	91.0	180	100	904	86.7	NA	NA	1,777	98.0	9,382	92.3
	Ciprofloxacin	1,223	92.6	3,164	87.0	1,134	95.2	629	96.5	2,324	94.2	10,198	90.5
	Gentamicin	1,157	97.2	3,562	93.8	1,169	89.4	629	93.0	2,568	97.6	12,426	92.3
	TMP-SMX	1,048	90.6	3,532	85.7	1,122	88.6	631	88.6	2,625	96.0	12,011	90.6
Citrobacter spp.	Cefotaxime	350	77.7	657	81.6	136	87.5	106	88.7	208	78.9	1,024	78.6
	Ceftazidime	361	74.0	403	76.7	165	81.8	95	83.2	280	80.4	1,566	72.2
	Ceftriaxone	NA	NA	NA	NA	131	88.6	NA	NA	251	82.9	1,509	75.6
	Ciprofloxacin	336	81.6	514	90.3	169	95.3	125	91.2	338	90.8	1,591	88.1
	Gentamicin	350	89.7	651	96.5	176	98.9	125	97.6	369	88.9	1,956	91.3
	TMP-SMX	321	85.4	641	96.1	163	92.6	125	93.6	379	87.3	1,891	89.6
Enterobacter spp.	Cefotaxime	1,806	58.1	2,190	70.8	779	63.5	581	78.0	1,126	79.8	2,413	73.1
	Ceftazidime	1,926	49.7	1,421	63.4	979	57.6	579	71.7	1,602	81.8	3,471	70.7
	Ceftriaxone	180	40.0	151	74.2	731	64.8	NA	NA	1,467	81.1	3,314	73.7
	Ciprofloxacin	1,855	59.2	1,920	89.6	988	77.6	689	98.3	1,949	94.3	3,615	93.4
	Gentamicin	1,797	94.3	2,213	95.1	1,000	85.7	686	98.7	2,082	96.3	4,394	95.7
	TMP-SMX	1,681	71.7	2,140	94.1	955	81.7	688	95.6	2,127	94.9	4,194	96.1
S. marcescens	Cefotaxime	806	81.5	1,041	94.5	352	83.8	265	94.3	791	95.2	3,531	85.4
	Ceftazidime	808	95.7	728	90.1	492	85.4	239	95.8	1,205	97.2	5,254	88.6
	Ceftriaxone	128	68.0	168	51.2	331	88.2	NA	NA	994	96.1	5,104	89.4
	Ciprofloxacin	792	77.7	1,031	61.7	498	88.4	307	93.2	1,436	86.7	5,406	90.2
	Gentamicin	809	90.7	1,003	91.7	495	96.8	307	96.1	1,447	93.6	6,510	93.2
	TMP-SMX	706	79.6	977	85.8	429	87.0	307	97.7	1,461	93.0	6,352	95.7
H. influenzae	Cefotaxime	2,381	100	1,124	100	336	100	1,776	100	421	100	774	100
	Ceftazidime	NA	NA	837	100	224	100	NA	NA	NA	NA	75	100
	Ceftriaxone	159	100	NA	NA	334	100	124	100	216	100	1,578	100
	Ciprofloxacin	389	100	1,032	100	411	100	1,524	100	420	100	243	100
	Gentamicin	2,230	74.2	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	TMP-SMX	2,492	74.4	1,100	84.7	633	86.3	1,617	60.4	1,736	79.8	2,138	81.0
P. aeruginosa	Amikacin	9,072	68.1	2,632	91.7	4,729	80.8	2,857	96.9	4,479	81.2	26,459	85.8
	Cefepime	8,534	54.5	3,660	76.6	2,737	61.2	2,991	70.1	805	64.5	24,118	70.7
	Cefotaxime	NA	NA	2,402	5.5	3,538	8.7	1,768	12.7	1,789	25.0	12,781	12.3
	Ceftazidime	9,031	70.9	4,873	79.8	5,700	59.4	3,178	73.4	7,666	74.7	32,069	71.5
	Ceftriaxone	NA	NA	88	22.7	3,165	8.8	154	57.1	3,377	16.3	16,504	16.0
	Ciprofloxacin	9,057	57.3	4,737	66.0	5,405	57.8	3,182	71.2	7,529	63.0	32,012	61.0
	Gentamicin	7,993	42.4	4,581	72.1	5,571	53.3	3,163	65.8	7,516	67.0	35,769	67.1
	Imipenem	9,076	69.8	4,435	70.8	5,418	63.1	3,039	71.4	5,416	77.6	30,949	74.0
	Piperacillin-tazobactam	8,598	71.3	4,624	88.9	2,916	81.9	2,926	80.2	5,127	88.7	25,157	84.9

^aLower respiratory tract isolates included those from sputum, bronchial washings, and tracheal aspirates. Data are cumulative for 2000 to 2001.

^bNA, not available, <50 results were available.